Type Congenic; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N13+F1pN1
Generation DefinitionsDonating Investigator Vladimir Buchman, Cardiff University School of Biosciences Description
Mice homozygous for this γ-synuclein mutant allele are viable and fertile with no obvious abnormalities in development, behavior, or gross morphology of the nervous system. No RNA or protein expression from the targeted gene is observed. Slight upregulation of β-synuclein is reported in the midbrain of homozygous mice. Homozygous mice are also resistant to the inflammatory/apoptotic Parkinson's disease-like pathology that results following MPTP neurotoxin administration (the active form of which (MPP+) gains entry into dopaminergic cells via the dopamine transporter (DAT)). These γ-synuclein mutant mice may be useful in studying synuclein function in neurodegenerative diseases, such as Parkinson's disease.Development
A targeting vector was designed to replace exons 1-3 of the targeted gene with a PGK-neo cassette. The construct was electroporated into 129P2/OlaHsd derived E14TG2a embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts and the resulting chimeric animals were bred with C57BL/6J inbred mice. Next, mutant mice were backcrossed to C57BL/6J for at least 12 generations prior to arrival at The Jackson Laboratory. Upon arrival, mice were bred with C57BL/6J inbred mice (Stock No. 000664) to establish the colony.
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Parkinson's Disease Models
005987 129-Achetm1Loc/J 007587 129S-Park2tm1Rpa/J 002779 129S-Parp1tm1Zqw/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 004608 B6(Cg)-Htra2mnd2/J 008133 B6.129-Sncbtm1Sud/J 008084 B6.129P2-Drd4tm1Dkg/J 004744 B6.129P2-Esr1tm1Ksk/J 013586 B6.129P2-Gt(ROSA)26Sortm1Nik/J 002609 B6.129P2-Nos2tm1Lau/J 016566 B6.129S-Hcn1tm2Kndl/J 004322 B6.129S1-Mapk10tm1Flv/J 003190 B6.129S2-Drd2tm1Low/J 006582 B6.129S4-Park2tm1Shn/J 005934 B6.129S4-Ucp2tm1Lowl/J 004936 B6.129S6(Cg)-Spp1tm1Blh/J 012453 B6.129X1(FVB)-Lrrk2tm1.1Cai/J 017009 B6.129X1-Nfe2l2tm1Ywk/J 009346 B6.Cg-Lrrk2tm1.1Shn/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 006577 B6.Cg-Park7tm1Shn/J 000567 B6.Cg-T2J +/+ Qkqk-v/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003139 B6.Cg-Tg(DBHn-lacZ)8Rpk/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 012466 B6.Cg-Tg(Lrrk2)6Yue/J 012467 B6.Cg-Tg(Lrrk2*G2019S)2Yue/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 007894 B6.Cg-Tg(Rgs4-EGFP)4Lvt/J 012588 B6.Cg-Tg(TH-ALPP)1Erav/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008601 B6.Cg-Tg(Th-cre)1Tmd/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 000544 B6.D2-Cacna1atg/J 012445 B6.FVB-Tg(LRRK2)WT1Mjfa/J 012446 B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J 006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 009688 B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 009347 B6;129-Lrrk2tm1.1Shn/J 016209 B6;129-Lrrk2tm2.1Shn/J 016210 B6;129-Lrrk2tm3.1Shn/J 013050 B6;129-Pink1tm1Aub/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 008532 B6;129-Thtm1(cre/Esr1)Nat/J 008333 B6;129P2-Dldtm1Ptl/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003243 B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J 003692 B6;129X1-Sncatm1Rosl/J 016575 B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J 016576 B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 000231 B6;C3Fe a/a-Csf1op/J 013725 B6;SJL-Tg(LRRK2)66Youy/J 016555 B6;SJL-Tg(Nqo1-ALPP)1Jaj/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 000506 B6C3Fe a/a-Qkqk-v/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 012441 C57BL/6J-Tg(tetO-LRRK2*G2019S)E3Cai/J 012450 C57BL/6J-Tg(tetO-SNCA)1Cai/J 016120 C57BL/6N-Lrrk1tm1.1Youy/J 016121 C57BL/6N-Lrrk2tm1.1Youy/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Youy/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Youy/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 009610 FVB/N-Tg(LRRK2)1Cjli/J 009609 FVB/N-Tg(LRRK2*G2019S)1Cjli/J 009604 FVB/N-Tg(LRRK2*R1441G)135Cjli/J 009090 FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010788 FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 000942 STOCK Pitx3ak/2J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 006340 STOCK Tg(Gad1-EGFP)98Agmo/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 008132 STOCK Tg(THY1-Snca)M1mSud/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Parkinson's Disease Models (99 strains)
Strains carrying other alleles of Sncg
012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J View Strains carrying other alleles of Sncg (1 strain)
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
Sncgtm1Vlb/Sncgtm1Vlb
B6.129P2-Sncgtm1Vlb
- nervous system phenotype
- *normal* nervous system phenotype
- homozygotes are viable, fertile and display no morphological or functional abnormalities of the nervous system relative to wild-type controls (MGI Ref ID J:86439)
- normal numbers of motoneurons in five brain stem motor nuclei, including facial, oculomotor, hypoglossal, trigeminal motor, and trochlear nuclei (MGI Ref ID J:86439)
- normal numbers of sensory neurons in trigeminal ganglia and L6 lumbar dorsal root ganglia (MGI Ref ID J:86439)
- normal morphology and numbers of myelinated A-fibers and unmyelinated C-fibers in adult saphenous nerves (MGI Ref ID J:86439)
- normal survival characteristics of P2 trigenimal ganglion neurons in various culture conditions (MGI Ref ID J:86439)
- normal sensory recovery after chronic constriction injury (CCI) to the sciatic nerve, suggesting that nerve regeneration and plasticity of early somatosensory pathways remains intact (MGI Ref ID J:86439)
- no significant differences in dopamine or its metabolite (DOPAC, 5-HIAA and HVA) levels in the striatum at 9 months of age (MGI Ref ID J:92213)
- decreased dopaminergic neuron number
- early postnatal (P5) and adult (18 months) homozygotes show a similar (15-20%) reduction in the number of tyrosine hydroxylase (TH)-positive dopaminergic neurons in substantia nigra pars compacta (SNpc) but not in ventral tegmental area (VTA) relative to wild-type controls (MGI Ref ID J:92213)
- however, no differences in the number of midbrain dopaminergic neurons are detected in SNpc at E18 (MGI Ref ID J:92213)
- also, no significant decrease in the number of TH-positive dopaminergic neurons is noted in SNpc after methyl-phenyl-tetrahydropyridine (MPTP) treatment relative to controls (MGI Ref ID J:92213)
- decreased susceptibility to dopaminergic neuron neurotoxicity
- homozygotes display resistance of SNpc dopaminergic neurons to MPTP neurotoxicity (MGI Ref ID J:92213)
- homeostasis/metabolism phenotype
- decreased susceptibility to dopaminergic neuron neurotoxicity
- homozygotes display resistance of SNpc dopaminergic neurons to MPTP neurotoxicity (MGI Ref ID J:92213)
- behavior/neurological phenotype
- *normal* behavior/neurological phenotype
- adult male homozygotes show normal behavioral reflex responses to noxious radiant heat and graded mechanical stimuli in the CCI model of neuropathic pain (MGI Ref ID J:86439)
- homozygotes are behaviorally normal and show no detectable motor dysfunction in either constant speed or accelerating rotarod tests (MGI Ref ID J:92213)
- cellular phenotype
- decreased susceptibility to dopaminergic neuron neurotoxicity
- homozygotes display resistance of SNpc dopaminergic neurons to MPTP neurotoxicity (MGI Ref ID J:92213)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Neurobiology Research
Neurodegeneration
Parkinson's Disease
resistance to MPTP
synuclein mutants
| Allele Symbol | Sncgtm1Vlb | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Vladimir L Buchman | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | TgHSNCGtm1VLB; | ||
| Mutation Made By | Vladimir Buchman, Cardiff University School of Biosciences | ||
| Strain of Origin | 129P2/OlaHsd | ||
| ES Cell Line Name | E14TG2a | ||
| ES Cell Line Strain | 129P2/OlaHsd | ||
| Gene Symbol and Name | Sncg, synuclein, gamma | ||
| Chromosome | 14 | ||
| Gene Common Name(s) | BCSG1; C79089; EST C79089; SR; persyn; | ||
| Molecular Note | Exons 1 through 3 were replaced with a neomycin selection cassette inserted by homologous recombination. Transcript was undetected in homozygous mutant mice by Northern blot analysis of RNA obtained from various tissues. Western blot analysis of total spinal cord protein indicated an absence of protein in homozygous mutant mice. [MGI Ref ID J:86439] | ||
Genotyping Protocols
Sncgtm1Vlb, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Ninkina N; Papachroni K; Robertson DC; Schmidt O; Delaney L; O'Neill F; Court F; Rosenthal A; Fleetwood-Walker SM; Davies AM; Buchman VL. 2003. Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol 23(22):8233-45. [PubMed: 14585981] [MGI Ref ID J:86439]
Senior SL; Ninkina N; Deacon R; Bannerman D; Buchman VL; Cragg SJ; Wade-Martins R. 2008. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27(4):947-57. [PubMed: 18333965] [MGI Ref ID J:132938]
Sncgtm1Vlb relatedAl-Wandi A; Ninkina N; Millership S; Williamson SJ; Jones PA; Buchman VL. 2010. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging 31(5):796-804. [PubMed: 19097673] [MGI Ref ID J:159589]
Anwar S; Peters O; Millership S; Ninkina N; Doig N; Connor-Robson N; Threlfell S; Kooner G; Deacon RM; Bannerman DM; Bolam JP; Chandra SS; Cragg SJ; Wade-Martins R; Buchman VL. 2011. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 31(20):7264-74. [PubMed: 21593311] [MGI Ref ID J:173360]
Burre J; Sharma M; Tsetsenis T; Buchman V; Etherton M; Sudhof TC. 2010. {alpha}-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro. Science :. [PubMed: 20798282] [MGI Ref ID J:164218]
Greten-Harrison B; Polydoro M; Morimoto-Tomita M; Diao L; Williams AM; Nie EH; Makani S; Tian N; Castillo PE; Buchman VL; Chandra SS. 2010. alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A 107(45):19573-8. [PubMed: 20974939] [MGI Ref ID J:167549]
Nguyen JV; Soto I; Kim KY; Bushong EA; Oglesby E; Valiente-Soriano FJ; Yang Z; Davis CH; Bedont JL; Son JL; Wei JO; Buchman VL; Zack DJ; Vidal-Sanz M; Ellisman MH; Marsh-Armstrong N. 2011. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci U S A 108(3):1176-81. [PubMed: 21199938] [MGI Ref ID J:168848]
Papachroni K; Ninkina N; Wanless J; Kalofoutis AT; Gnuchev NV; Buchman VL. 2005. Peripheral sensory neurons survive in the absence of alpha- and gamma-synucleins. J Mol Neurosci 25(2):157-64. [PubMed: 15784963] [MGI Ref ID J:121324]
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL. 2004. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem 89(5):1126-36. [PubMed: 15147505] [MGI Ref ID J:92213]
Senior SL; Ninkina N; Deacon R; Bannerman D; Buchman VL; Cragg SJ; Wade-Martins R. 2008. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27(4):947-57. [PubMed: 18333965] [MGI Ref ID J:132938]
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, RG10/RG30.Colony Maintenance
Breeding & Husbandry When maintaining a live colony, homozygous mice may be bred.
| Pricing for USA, Canada and Mexico shipping destinations |
|
![]() |
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $1980.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.
Supply Notes
- Cryorecovery - Standard.
We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 13 and 16 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
![]() |
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2574.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.
Supply Notes
- Cryorecovery - Standard.
We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 13 and 16 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.